Guides Collective
The Weekly Guide
Resources, research, and reflections — curated each week for the guides in our community.
AUG 21, 2026
From the Platform
What's new and coming to Guides Collective.
We're still pushing national ads to next week's educational webinar to bring on new seekers to the platform.
Working through bugs, bugs, and more bugs :)
Section 01
Personal Journeys
First-person accounts worth reading. Perspectives that inform the work we do.
NORMALIZE PSYCHEDELICS · DECEMBER 9, 2025
Healing From Addiction With Ibogaine: Jen Bruce's Story
Jen Bruce spent 17 years struggling with alcohol addiction before finding sobriety through the Twelve Steps — but five years in, she was still battling depression, anxiety, and chronic pain. She traveled to Mexico for ibogaine, calling it "the medicine they tell us in recovery doesn't exist." She now describes reviewing her most traumatic memories with no emotional charge at all, and works helping others integrate psychedelics into their own recovery.
NORMALIZE PSYCHEDELICS · OCTOBER 7, 2025
The Youngest City Councilman in Montana on Psychedelics and Civil Disobedience
Daniel Carlino, the youngest city council member in Missoula, Montana, says transformative experiences with psilocybin and DMT shaped his politics and pushed him toward decriminalizing plant medicines at the local level. "If every politician had a psychedelic experience," he says, "I think we would be getting way better outcomes."
Section 02
From the Field
Perspectives and insights from leaders in the psychedelic space.
MEDICAL XPRESS · AUGUST 6, 2026
UK's First Publicly Funded Psilocybin Trial Shows Strong Results for Depression
In the UK's first publicly funded psilocybin trial, a single 25mg dose produced significantly greater improvement in treatment-resistant depression than placebo — 50% of participants responded by week six, versus just 3% on placebo, with similar gaps in remission rates. The trial also showed the therapy could be safely delivered in community mental health settings rather than hospitals, opening the door to larger studies.
MEDICAL XPRESS · AUGUST 21, 2026
Real-World Data From 2,300+ Psilocybin Users Backs Up the Clinical Trials
Tracking 2,363 clients at regulated psilocybin centers in Oregon and Colorado, researchers found depression and anxiety scores dropped by roughly 50% within two weeks of dosing, with 50-60% of clients seeing at least half their symptoms resolve. Adverse effects were mostly mild and short-lived, though the team flagged a small subset with increased suicidal ideation as something to keep monitoring as these services expand beyond clinical trials.
Section 03
Industry Headlines
What's happening in the psychedelic space this week.
PSYCHEDELIC ALPHA · AUGUST 18, 2026
J&J to Lead $85 Million Series C for Non-Hallucinogenic Psychedelic Developer Delix
Johnson & Johnson is leading an $85 million Series C round for Delix Therapeutics at a $190 million pre-money valuation. Delix develops neuroplastogens — compounds designed to deliver psychedelics' therapeutic brain-rewiring effects without the hallucinogenic trip — and its lead candidate, zalsupindole, is currently in Phase II trials for major depressive disorder.
BIOSPACE · AUGUST 19, 2026
Trump's Pick for FDA Commissioner Seen as a Win for Psychedelics
Analysts say Dr. Heidi Overton's nomination to lead the FDA bodes well for psychedelic drug developers, pointing to her visible role running the April 2026 executive order that prioritized FDA review of ibogaine and MDMA-based therapies. BMO Capital Markets called her involvement a clear signal of "the administration's approach to use of psychedelics as medicine."
PSYCHEDELIC ALPHA · AUGUST 20, 2026
Stakeholders Flood HRSA With Ideas for Delivering Psychedelic Therapy at Scale
HRSA's request for information on preparing the healthcare workforce for potential FDA-approved psychedelic therapies drew 59 comments from drug developers, care-delivery companies, advocacy groups, and professional associations. Submissions clustered around three themes — clinician training, clinic-based delivery models, and technology-enabled scalability — aimed at reaching underserved rural and vulnerable populations if these treatments are approved.